

BUSINESS OPERATIONS

A *Chlamydomonas reinhardtii* cells were grown in the presence of 100 μM DMSO or 100 μM of the indicated compounds. Cells were harvested and total RNA was isolated. The amount of *hsp70* mRNA was determined by Northern blot analysis. **B** *Chlamydomonas reinhardtii* cells were grown in the presence of 100 μM DMSO or 100 μM of the indicated compounds. Cells were harvested and total RNA was isolated. The amount of *hsp70* mRNA was determined by Northern blot analysis. **C** *Chlamydomonas reinhardtii* cells were grown in the presence of 100 μM DMSO or 100 μM of the indicated compounds. Cells were harvested and total RNA was isolated. The amount of *hsp70* mRNA was determined by Northern blot analysis.

PUBLIC FLOAT STATUS AND OWNERSHIP COMPOSITION OF THE H SHARES OF THE COMPANY

A
H C

	Number of Shares	Approximate percentage of the Company's issued share capital (deducting 1,959,800 H Shares that have been repurchased but not yet cancelled) as at the date of this announcement
Domestic Shares	52,760,000	74.94%
H Shares (deducting 1,959,800 H Shares that have been repurchased but not yet cancelled):	17,639,100	25.06%
Number of H Shares held by the non-public persons:	667,400	0.95%
• A G ()	149,300	0.21%
• A G ()	209,100	0.30%
• A G H ()		
• A G ()	309,000	0.44%
Number of H Shares held by the public:	16,971,700	24.11%
• A C	1,454,000	2.07%
• C C	2,150,900	3.06%
• F	1,279,900	1.82%
• ,	1,052,000	1.49%
B G AG	1,029,400	1.46%
H	1,680,000	2.39%
• H	3,347,975	4.76%
•	4,977,525	7.07%
Total	70,399,100	100%

本公司董事、监事、高级管理人员、控股股东、实际控制人、主要关联方及持股5%以上股份的股东均不存在与本公司控股股东、实际控制人、主要关联方及持股5%以上股份的股东之间存在关联关系的情形。本公司董事、监事、高级管理人员、控股股东、实际控制人、主要关联方及持股5%以上股份的股东均不存在与本公司控股股东、实际控制人、主要关联方及持股5%以上股份的股东之间存在关联关系的情形。

Shareholders and potential investors of the Company should exercise caution when dealing in the Shares.

B
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
C

2026年2月2日

A
A G
C
CHA
A G
H G
H